Influence of Androgen Receptor Antagonist MDV3100 Therapy on Rats With Benign Prostatic Hyperplasia
1
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Purpose: To probe the effect and mechanism of androgen receptor antagonist MDV3100 on benign prostatic hyperplasia (BPH) of rats Methods: BPH rat model was induced by testosterone propionate. Then antagomir-miR-21-3p or agomir-miR-21-3p was injected into rats before MDV3100 treatment. The prostate index was measured by weighing the wet weight of the rat prostate. The structural morphology of rat prostate was observed after hematoxylin & eosin staining. Immunohistochemistry was applied to evaluate the expression levels of Ki-6 and inflammatory cytokines (interleukin [IL]-6, IL-18, and tumor necrosis factor-α) in rat prostate tissues. Quantitative reverse transcription polymerase chain reaction was utilized for assessment of miR-21-3p expression, and Western blot for the performance of the phosphorylation levels of IKKα and p65. Results: Injection of testosterone propionate caused increased prostate gland hyperplasia, heightened miR-21-3p level, and activated nuclear factor-kappa B (NF-κB) signaling pathway. Additionally, BPH was accompanied by inflammatory response, as evidenced by enhanced expressions of Ki-67 and inflammatory cytokines. MDV3100 exposure ameliorated BPH and suppressed miR-21-3p expression. Overexpression of miR-21-3p intensified BPH and inflammation level, while knockdown of miR-21-3p relieved BPH. The coeffect of miR-21-3p upregulation and MDV3100 subjection led to higher inflammatory response, elevated phosphorylation levels of IKKα and p65 than MDV3100 treatment alone. Conclusions: Androgen receptor antagonist MDV3100 alleviates BPH and inflammatory response through miR-21-3p downregulation and NF-κB signaling pathway blockade.
Abstract
Purpose: To probe the effect and mechanism of androgen receptor antagonist MDV3100 on benign prostatic hyperplasia (BPH) of rats Methods: BPH rat model was induced by testosterone propionate. Then antagomir-miR-21-3p or agomir-miR-21-3p was injected into rats before MDV3100 treatment. The prostate index was measured by weighing the wet weight of the rat prostate. The structural morphology of rat prostate was observed after hematoxylin & eosin staining. Immunohistochemistry was applied to evaluate the expression levels of Ki-6 and inflammatory cytokines (interleukin [IL]-6, IL-18, and tumor necrosis factor-α) in rat prostate tissues. Quantitative reverse transcription polymerase chain reaction was utilized for assessment of miR-21-3p expression, and Western blot for the performance of the phosphorylation levels of IKKα and p65. Results: Injection of testosterone propionate caused increased prostate gland hyperplasia, heightened miR-21-3p level, and activated nuclear factor-kappa B (NF-κB) signaling pathway. Additionally, BPH was accompanied by inflammatory response, as evidenced by enhanced expressions of Ki-67 and inflammatory cytokines. MDV3100 exposure ameliorated BPH and suppressed miR-21-3p expression. Overexpression of miR-21-3p intensified BPH and inflammation level, while knockdown of miR-21-3p relieved BPH. The coeffect of miR-21-3p upregulation and MDV3100 subjection led to higher inflammatory response, elevated phosphorylation levels of IKKα and p65 than MDV3100 treatment alone. Conclusions: Androgen receptor antagonist MDV3100 alleviates BPH and inflammatory response through miR-21-3p downregulation and NF-κB signaling pathway blockade.
참고문헌 (32)
- Langan RC, "Benign prostatic hyperplasia", Prim Care, 46, pp.223~232 (2019)
- Rastrelli G, "Testosterone and benign prostatic hyperplasia", Sex Med Rev, 7, pp.259~271 (2019)
- Lee HN, "Effects of doxazosin on alpha 1-adrenergic receptors in prostates with benign prostatic hyperplasia", Low Urin Tract Symptoms, 5, pp.82~89 (2013)
- Alcaraz A, "Is there evidence of a relationship between benign prostatic hyperplasia and prostate cancer? Findings of a literature review", Eur Urol, 55, pp.864~873 (2009)
- Koohi Hosseinabadi O, "Benign prostatic hyperplasia treatment using plasmonic nanoparticles irradiated by laser in a rat model", Biomed Pharmacother, 127, pp.110118~ (2020)
- Bluemn EG, "Androgen receptor pathway-independent prostate cancer is sustained through fgf signaling", Cancer Cell, 32, pp.474~489 (2017)
- Steinestel J, "Detecting predictive androgen receptor modifications in circulating prostate cancer cells", Oncotarget, 10, pp.4213~4223 (2019)
- Li H, "Characterization of a new class of androgen receptor antagonists with potential therapeutic application in advanced prostate cancer", Mol Cancer Ther, 12, pp.2425~2435 (2013)
- Benoist GE, "Prognostic value of novel liquid biomarkers in patients with metastatic castration-resistant prostate cancer treated with enzalutamide : a prospective observational study", Clin Chem, 66, pp.842~851 (2020)
- Rathkopf D, "Androgen receptor antagonists in castration-resistant prostate cancer", Cancer J, 19, pp.43~49 (2013)
- Tornatore L, "The nuclear factor kappa B signaling pathway : integrating metabolism with inflammation", Trends Cell Biol, 22, pp.557~566 (2012)
- Zhu WD, "MicroRNA-21 inhibits lipopolysaccharide-induced acute lung injury by targeting nuclear factor-kappaB", Exp Ther Med, 16, pp.4616~4622 (2018)
- Thomas-Jardin SE, "NFkappaB signaling promotes castration-resistant prostate cancer initiation and progression", Pharmacol Ther, 211, pp.107538~ (2020)
- Zhang N, "MicroRNA expression profiles in benign prostatic hyperplasia", Mol Med Rep, 17, pp.3853~3858 (2018)
- Cochetti G, "Different levels of serum microRNAs in prostate cancer and benign prostatic hyperplasia : evaluation of potential diagnostic and prognostic role", Onco Targets Ther, 9, pp.7545~7553 (2016)
- Tanaka T, "Urine miR-21-5p as a potential biomarker for predicting effectiveness of tadalafil in benign prostatic hyperplasia", Future Sci OA (2018)
- Lakhter AJ, "Beta cell extracellular vesicle miR-21-5p cargo is increased in response to inflammatory cytokines and serves as a biomarker of type 1 diabetes", Diabetologia, 61, pp.1124~1134 (2018)
- Sirotkin AV, "MicroRNAs control transcription factor NF-kB(p65)expression in human ovarian cells", Funct Integr Genomics, 15, pp.271~275 (2015)
- Yang Y, "The functional analysis of MicroRNAs involved in NF-kappaB signaling", Eur Rev Med Pharmacol Sci, 20, pp.1764~1774 (2016)
- Wu J, "MicroRNA roles in the nuclear factor kappa B signaling pathway in cancer", Front Immunol, 9, pp.546~ (2018)
- Li J, "Testosterone-induced benign prostatic hyperplasia rat and dog as facile models to assess drugs targeting lower urinary tract symptoms", PLoS One, 13, pp.e0191469~ (2018)
- Kim EH, "Management of benign prostatic hyperplasia", Annu Rev Med, 67, pp.137~151 (2016)
- Popovics P, "Prostatic osteopontin expression is associated with symptomatic benign prostatic hyperplasia", Prostate, 80, pp.731~741 (2020)
- Mobley D, "Benign prostatic hyperplasia and urinary symptoms : evaluation and treatment", Postgrad Med, 127, pp.301~307 (2015)
- Han J, "Abiraterone and MDV3100 inhibits the proliferation and promotes the apoptosis of prostate cancer cells through mitophagy", Cancer Cell Int, 19, pp.332~ (2019)
- Sternberg CN, "Enzalutamide, an oral androgen receptor inhibitor for treatment of castration-resistant prostate cancer", Future Oncol, 15, pp.1437~1457 (2019)
- Guan Y, "Association of microRNA-21expression with clinicopathological characteristics and the risk of progression in advanced prostate cancer patients receiving androgen deprivation therapy", Prostate, 76, pp.986~993 (2016)
- Dong B, "IL-6 inhibits the targeted modulation of PDCD4 by miR-21 in prostate cancer", PLoS One, 10, pp.e0134366~ (2015)
- Liu T, "NF-kappaB signaling in inflammation", Signal Transduct Target Ther, 2, pp.17023~ (2017)
- Staal J, "Inflammation and NF-kappaB signaling in prostate cancer : mechanisms and clinical implications", Cells, 7, pp.122~ (2018)
- Ni SJ, "CBX7regulates stem cell-like properties of gastric cancer cells via p16 and AKT-NF-kappaB-miR-21 pathways", J Hematol Oncol, 11, pp.17~ (2018)
- Pan YQ, "Effect of miR-21", TLR4, Eur Rev Med Pharmacol Sci, pp.2018, 22[DOI]